Showing 1 - 4 results of 4 for search 'A. Risitano', query time: 0.02s Refine Results
  1. 1
    P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA

    P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA by A. Risitano, R. Wong, M. Al-Adhami, J. Savage, R. Horneff, R. Peffault de Latour

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS

    P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏV... by A. McDonald, J. L. R. Malherbe, A. Kulasekararaj, W. Füreder, M. Griffin, M. Cornpropst, M. K. Farmer, D. Kargl, D. Collins, W. Sheridan, A. Risitano

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

    P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CON... by A. Kulasekararaj, W. Füreder, A. McDonald, J. L. R. Malherbe, S. Gandhi, D. Collins, M. Cornpropst, S. Dobo, M. K. Farmer, D. Kargl, W. Sheridan, M. Griffin, A. Risitano

    Published 2022-06-01
    Get full text
    Article
  4. 4
    RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINU... by H. Weitz, P. Hillmen, J. Szer, A. Röth, B. Höchsmann, J. Panse, K. Usuki, M. Griffin, J. Kiladjian, C. Decastro, H. Nishimori, L. Tan, M. Hamdani, P. Deschatelets, C. Francois, F. Grossi, A. Risitano, R.P. Latour

    Published 2020-11-01
    Get full text
    Article

Search Tools: